Quantum BioPharma Ltd (QNTM)

Quantum BioPharma Ltd. is a healthcare company listed on NASDAQ under the symbol QNTM. Through its subsidiaries, the company operates in two segments: Biopharmaceutical Innovation and Strategic Investments. Its research and development efforts focus on therapies for neurodegenerative, inflammatory, and metabolic disorders, as well as alcohol misuse disorders, with several drug candidates at different stages of development. The company’s lead program, Lucid-MS, is a patented new chemical entity in Phase 2 clinical testing and is being studied for its potential to help prevent and reverse myelin degradation associated with multiple sclerosis in preclinical models. Other pipeline assets include FSD-PEA, which is being prepared for Phase 2 evaluation for inflammatory conditions such as mast cell activation syndrome, Lucid-PSYCH for major depressive disorder, and unbuzzd, a dietary supplement related to alcohol misuse. In addition to its biopharmaceutical activities, Quantum BioPharma maintains a portfolio of strategic investments that includes loans secured by residential property. Formerly known as FSD Pharma Inc., the company adopted its current name in August 2024 and is headquartered in Toronto, Canada.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.